Barclays
CAI

Barclays’s Caris Life Sciences CAI Stock Holding History

Barclays’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$735K Sell
41,228
-33,195
-45% -$594K ﹤0.01% 2971
2026
Q1 		$1.33M Buy
74,423
+20,306
+38% +$444K ﹤0.01% 2578
2025
Q4 		$1.46M Buy
54,117
+50,940
+1,603% +$1.43M ﹤0.01% 3161
2025
Q3 		$96.1K Sell
3,177
-6,823
-68% -$218K ﹤0.01% 4627
2025
Q2 		$267K Buy
+10,000
New +$270K ﹤0.01% 4105

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Barclays's CAI Position: Q2 2026 in Review

Barclays reduced its Caris Life Sciences (CAI) stake by 45% in Q2 2026, selling an estimated $594K and leaving 41,228 shares worth $735K. The position accounts for ﹤0.01% of the portfolio, ranked #2971.

Barclays first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.46M in Q4 2025. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Barclays held 41,228 shares of Caris Life Sciences worth $735K as of Q2 2026.
  • Barclays sold 33,195 Caris Life Sciences shares in Q2 2026, an estimated $594K.
  • Caris Life Sciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2971 holding.
  • Barclays first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • Barclays's Caris Life Sciences position peaked at $1.46M in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.